More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus (RSV) for infants, will be available in January, the White House says. The announcement comes as ...

The Beyfortus antibody shot, manufactured by drugmakers AstraZeneca and Sanofi, was approved by the Food and Drug Administration in July as a way to prevent RSV in infants and children up to 24 ...

The monoclonal antibody from Sanofi and AstraZeneca, called Beyfortus, is the first of its kind likely to be widely available to everyone up to 24 months of age beyond a small population of ...

Called Nirsevimab, the shot will be sold under the brand name Beyfortus. It is a ready-made antibody that can block the RSV virus from infecting cells. Technically, it's not a vaccine, but a ...

The Food and Drug Administration announced Monday that it has approved the new drug Beyfortus in an effort to fight the spread of Respiratory Syncytial Virus (RSV) lower respiratory tract disease ...